Comprehensive Eye Care & Vision Correction in Incheon · Multilingual International Concierge

23+ Years Clinical Experience

en-US

Global Ubal Eye CenterHome
Book Consultation
Book Consultation
Patient Guide
SpecialtiesServicesDoctorsOffersArticlesReviewsAbout UsContact Us
Macular Degeneration in 2025: Latest Breakthroughs in Treatment

Ophthalmology Guide

Macular Degeneration in 2025: Latest Breakthroughs in Treatment

Macular Degeneration in 2025: Discover new treatments—gene therapy, complement inhibitors & long-acting shots. Stay ahead of vision care; learn more now.

Schedule a Consultation

Introduction: A New Chapter in Macular Degeneration Care

Macular Degeneration

Not long ago, a diagnosis of macular degeneration often carried a heavy silence. Patients would ask, “Can anything be done?” and too often the answer was, “We’ll do our best to slow the inevitable.” For many, that meant preparing for a gradual loss of independence—reading glasses left unused, hobbies abandoned, and the unsettling thought of life without clear central vision.

Wet AMD: From Monthly Needles to Longer, Smarter Intervals

For many patients, the fear of AMD has as much to do with the treatment burden as the disease itself. Monthly injections are effective, but exhausting. In 2025, durability—not just efficacy—is the keyword.

High-Dose Anti-VEGF: Longer Control Without Sacrifice

The approval of Aflibercept 8 mg (Eylea HD) has given ophthalmologists a tool that stretches dosing intervals to 12–16 weeks in many patients. In practical terms, this means that instead of monthly visits, a patient may only need injections four times a year. The durability is real, and it matters most to those who work, care for family, or travel long distances for treatment.

Dual-Pathway Therapy: Faricimab’s Promise

Faricimab (Vabysmo) is the first drug to block both VEGF-A and Ang-2. This dual mechanism allows many patients to maintain stability with 12–16 week dosing. For those juggling multiple health issues—or who simply want more freedom—this is a meaningful improvement.

Susvimo Implant: Continuous Release, Twice-Yearly Refills

The Susvimo port delivery system has re-emerged after earlier refinements, offering sustained release of ranibizumab with refills only twice a year. While it requires minor surgery and carries unique risks, for carefully selected patients it can reduce the relentless cycle of monthly appointments.

Dry AMD & Geographic Atrophy: Real Options, Honest Expectations

Macular Degeneration

For decades, those with dry AMD—specifically the advanced form known as geographic atrophy (GA)—were told there was no treatment. Today, two new therapies are shifting that narrative.

Pegcetacoplan (Syfovre): Targeting C3

By inhibiting C3, pegcetacoplan slows the enlargement of GA lesions. Some data now suggest benefits not only in imaging but also in functional outcomes such as reading ability and low-light vision. It requires regular injections, often monthly or every other month, and carries rare but notable risks of inflammation.

Avacincaptad Pegol (Izervay): Targeting C5

This C5 inhibitor has shown consistent slowing of GA progression over two years, and in early 2025 its label was expanded, making longer-term use possible.

What’s Next: Pills and Cell Therapy

  • Danicopan, an oral Factor D inhibitor, is in advanced trials. If effective, it could reduce the need for frequent injections.
  • Gildeuretinol (ALK-001), a modified form of vitamin A, shows potential in slowing GA by addressing toxic byproducts of normal vision.
  • Cell therapies like OpRegen aim not just to slow loss but to replace damaged retinal pigment cells—a tantalizing step toward regeneration.

Gene Therapy: Toward a “One-and-Done” Approach

For years, the dream in retinal medicine has been simple: instead of endless injections, could we teach the eye to treat itself? That is the promise of gene therapy.

Home Monitoring and AI: Care Beyond the Clinic

Home Monitoring

If gene therapy represents the future of fewer procedures, AI and home monitoring represent the future of smarter care.

  • Earlier detection if fluid returns between visits.
  • Fewer unnecessary injections when the retina is stable.
  • Peace of mind for patients who often worry about silent disease activity.

The Human Side of 2025 AMD Care

It is easy to focus on numbers, lesion sizes, and trial data. But the true measure of success in AMD treatment is not only in millimeters on a scan—it is in the lived experience of patients.

  • Did a grandmother keep reading bedtime stories to her grandchildren?
  • Did an office worker remain productive at the job he loves?
  • Did an artist continue painting, finding joy in colors and forms, for a few more years?

Conclusion: From Hopelessness to Hopeful Stewardship

In 2025, macular degeneration is no longer defined by inevitability. For wet AMD, extended-interval injections and implants mean patients can live more freely, without monthly disruption. For dry AMD and geographic atrophy, the first generation of treatments now slows progression, preserving independence and quality of life.

More Articles

Continue reading our ophthalmology guides and vision care insights.

View All
SMILE vs LASIK: Recovery Benchmarks for Vision Correction Care

SMILE vs LASIK: Recovery Benchmarks for Vision Correction Care

South Korea has solidified its position as a global epicenter for ophthalmology, with the domestic LASIK and refractive surgery market projected to reach **USD 167.37 million by 2035**, growing at a steady CAGR of 8.54%.

Learn More

Learn More
Prevalence of Myopia in Korea: The Value of Dream Lens Therapy

Prevalence of Myopia in Korea: The Value of Dream Lens Therapy

The prevalence of myopia among young people in South Korea has reached critical levels, often described as a "myopia epidemic." According to recent data from the **Korean National Health and Nutrition Examination Survey (KNHANES)**, the prevalence of myopia...

Learn More

Learn More
Multidisciplinary Care: The Future of Korean Pediatric Eye Clinics

Multidisciplinary Care: The Future of Korean Pediatric Eye Clinics

The landscape of pediatric eye care in South Korea is shifting rapidly. With nearly **21.9% of Korean children** estimated to be affected by various visual disorders according to nationwide health screenings, the demand for specialized intervention has never...

Learn More

Learn More

Medical Clinic

Global Ubal Eye Center in Jung-gu, Incheon, South Korea provides precision LASIK, LASEK, cataract, presbyopia, glaucoma, and retinal care with dedicated multilingual support for international patients.

Treatments

SpecialtiesServicesMedical TeamSpecial OffersMedical Articles

Patient Guide

About UsHow It WorksPatient Reviews

Information & Legal

Contact & LocationSite SearchPrivacy PolicyRefund & Cancellation PolicyTerms of Use

© 2026 Global Ubal Eye Center. All rights reserved.

Individual clinical outcomes vary depending on ocular anatomy and diagnostic findings. Please consult a board-certified ophthalmologist.